Business
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM).
About this update from Gb Sciences, Inc.
[{"type":"text","content":"LAS VEGAS, NV / ACCESSWIRE / October 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of chronic inflammation. Chronic inflammation represents a serious global health and economic burden with over $130 billion spent annually. Based on data from a two-year study on the use of cannabis-based compounds for modulating inflammatory processes within human immune cells that was conducted for GBS by Dr. Norbert Kaminski at Michigan State University (MSU), GBS’ CCCM™ were designed to reduce chronic inflammation by targeting those immune cells and pro-inflammatory processes that contribute to the pathology of chronic inflammation. In particular, GBS is interested in developing therapeutics for patients with chronic neuroinflammation. Mounting evidence suggests that pro-inflammatory processes in the brain contribute to the pathologies of HIV-Associated Neurocognitive Disorder (HAND), Parkinson’s and Alzheimer’s diseases.The human primary blood cell screens performed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system, permitting assessment of the anti-inflammatory potential of GB Sciences’ neuroprotective compounds.“NIH funded research from my laboratory at MSU has demonstrated a relationship between cannabis use and a decrease in the number of circulating activated monocytes in HIV/AIDS patients who used cannabis versus those who did not,” explained Dr. Norbert Kaminski, Director of the Institute for Integrative Toxicology, Professor of Pharmacology & Toxicology, and Director of the Center for Research on Ingredient Safety at MSU. “These activated monocytes have been linked to HIV-Associated Neurocognitive Disorder (HAND) and are also believed to play a role in Parkinson’s and Alzheimer’s diseases. The study that we performed for GBS demonstrated that some cannabis-based compounds can decrease pro-inflammatory processes. These results suggest that cannabinoid-based mixtures may lead to future therapeutics for these debilitating neuroinflammatory conditions.”“We look forward to con...